Konrad Kauper has led the core device development programs for Neurotech’s Encapsulated Cell Technology (ECT) for the past 15 years. During this period Neurotech has successfully completed several Phase I, Phase II clinical trials and recently completed enrollment of two-Phase III US and multinational clinical trials investigating ECT as a treatment for eye disease including wet macular degeneration, retinitis pigmentosa, dry macular degeneration and macular telangiectasia.
Konrad has over 23 years of experience in biotechnology and pharmaceutical companies having held research and development positions at WR Grace Biomedical, CytoTherapeutics, and Genetics Institute, contributing multiple patents, peer-reviewed scientific articles and oral presentations related to the fields of drug delivery and cell-based therapeutics. Konrad received his undergraduate and graduate degrees in Chemical Engineering from Northeastern University.
,